Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhi, Lu, Qiliang, Liu, Yang, Zhao, Junjun, Zhang, Qian, Hu, Linjun, Shi, Zhan, Tu, Yifeng, Xiao, Zunqiang, Xu, Qiuran, Huang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292964/
https://www.ncbi.nlm.nih.gov/pubmed/34307125
http://dx.doi.org/10.3389/fonc.2021.641522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292964/
https://www.ncbi.nlm.nih.gov/pubmed/34307125
http://dx.doi.org/10.3389/fonc.2021.641522

Ejemplares similares